Home  |  Contact

UniProtKB/Swiss-Prot Q9NZN9: Variant p.Arg302Leu

Aryl-hydrocarbon-interacting protein-like 1
Gene: AIPL1
Variant information

Variant position:  302
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Leucine (L) at position 302 (R302L, p.Arg302Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Found in a patient with LCA4; there is no interaction with NUB1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  302
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  384
The length of the canonical sequence.

Location on the sequence:   EAKADLQKVLELEPSMQKAV  R RELRLLENRMAEKQEEERLR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EAKADLQKVLELEPSMQKAVRRELRLLENRMAEKQEEERLR

Rhesus macaque                EAKADLQKVLELEPSMQKAVRRELRLLENRMAEKQEEERLR

Mouse                         EAKADLEKVLELEPSMRKAVLRELRLLESRLADKQEEERQR

Rat                           EAKADLEKVLELEPSMRKAVLRELRLLESRLADKQEEERQR

Bovine                        EAKADLEKVLELEPSMRKAVQRELRLLENRLEEKREEERLR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 384 Aryl-hydrocarbon-interacting protein-like 1
Helix 298 – 312


Literature citations

The inherited blindness associated protein AIPL1 interacts with the cell cycle regulator protein NUB1.
Akey D.T.; Zhu X.; Dyer M.; Li A.; Sorensen A.; Blackshaw S.; Fukuda-Kamitani T.; Daiger S.P.; Craft C.M.; Kamitani T.; Sohocki M.M.;
Hum. Mol. Genet. 11:2723-2733(2002)
Cited for: INTERACTION WITH NUB1; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; MUTAGENESIS OF ARG-53; MET-79; VAL-96; ALA-197; ILE-206 AND GLY-262; CHARACTERIZATION OF VARIANT LEU-302; CHARACTERIZATION OF VARIANT LCA4 ARG-239;

Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients.
Simonelli F.; Ziviello C.; Testa F.; Rossi S.; Fazzi E.; Bianchi P.E.; Fossarello M.; Signorini S.; Bertone C.; Galantuomo S.; Brancati F.; Valente E.M.; Ciccodicola A.; Rinaldi E.; Auricchio A.; Banfi S.;
Invest. Ophthalmol. Vis. Sci. 48:4284-4290(2007)
Cited for: VARIANT LCA4 HIS-270; VARIANT LEU-302;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.